{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"15","value":"4.6"}]}],"title":"200 mg"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28","upperLimit":"210","value":"72.6"}]}],"title":"300 mg"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11","upperLimit":"496","value":"107.1"}]}],"title":"400 mg"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Event causing discontinuation from the study was defined as (1) progressive disease OR (2) intolerable toxicity.\n\nProgressive disease was defined as:\n\n* \\>25% increase in the level of serum monoclonal paraprotein.\n* 25% increase in 24-hour urinary light chain excretion.\n* \\>25% increase in plasma cells in a bone marrow aspirate or on trephine\n\nbiopsy.\n\n* Development of new bone lesions or soft tissue plasmacytomas.\n* Development of hypercalcemia.\n\nIntolerable toxicity was based on the clinical judgment of the investigator.","dispersionType":"Full Range","groups":[{"description":"Vorinostat capsules given 200 mg b.i.d., 300 mg q.d., or 400 mg q.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break).\n\nBortezomib injection. Treatment in 21 day cycles (participants received bortezomib 0.7 mg/m\\^2, 0.9 mg/m\\^2, 1.1 mg/m\\^2, or 1.3 mg/m\\^2 twice weekly on Days 1, 4, 8, and 11 or on Days 4, 8, 11, and 15 of each cycle, depending on dose level.","id":"OG000","title":"All Participants"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Day 1 to an event causing discontinuation from the study, assessed up to 29 months","title":"Mean Duration of Treatment With Vorinostat","type":"PRIMARY","unitOfMeasure":"Days"}